REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Earnings & Estimates
USA - NASDAQ:RVPH - US76152G1004 - Common Stock
0.4423 USD
0 (-0.18%)
0.4411 USD
0 (-0.27%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 173.78% | N/A 95.92% | N/A 57.12% | N/A 37.16% | |||||||
| EBITDA YoY % growth | N/A | -724.1K | -10.105M -1,295.46% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -152.8K | -724.7K -374.28% | -10.105M -1,294.30% | -28.229M -179.37% | -39.504M -39.94% | -30.799M 22.04% | N/A 2.51% | N/A -16.67% | N/A -15.99% | N/A 120.62% | N/A 1,306.71% | N/A 149.42% | N/A 75.72% | N/A 42.13% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -0.56 -222.95% | -1.25 -123.21% | -1.64 -31.20% | -0.91 44.51% | N/A 42.84% | N/A 5.49% | N/A 24.62% | N/A 212.85% | N/A 129.27% | N/A 100.00% | N/A 47.34% | N/A 27.44% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.11 55.12% | -0.12 20.10% | -0.11 17.62% | -0.10 15.00% | -0.16 -45.45% | -0.19 -61.70% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.302M 1.89% | -10.014M -59.34% | -8.61M -31.69% | -8.999M -48.18% | -10.537M -26.92% | -11.849M -18.32% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.12 53.85% | -0.11 | -0.01 | -6.95% |
| Q1 2025 Q2Q % growth | -0.13 48.00% | -0.19 | 0.06 | 30.16% |
| Q4 2024 Q2Q % growth | -0.15 57.14% | -0.22 | 0.07 | 31.60% |
| Q3 2024 Q2Q % growth | -0.25 43.18% | -0.25 | 0.00 | 0.37% |
| Q2 2024 Q2Q % growth | -0.26 52.73% | -0.30 | 0.04 | 12.10% |
| Q1 2024 Q2Q % growth | -0.25 16.67% | -0.38 | 0.13 | 34.93% |
| Q4 2023 Q2Q % growth | -0.35 7.89% | -0.36 | 0.01 | 2.66% |
| Q3 2023 Q2Q % growth | -0.44 -144.44% | -0.37 | -0.07 | -17.86% |
| Q2 2023 Q2Q % growth | -0.55 -89.66% | -0.28 | -0.27 | -95.37% |
| Q1 2023 Q2Q % growth | -0.30 25.00% | -0.33 | 0.03 | 9.50% |
| Q4 2022 Q2Q % growth | -0.38 -72.73% | -0.22 | -0.16 | -69.34% |
| Q3 2022 Q2Q % growth | -0.18 -50.00% | -0.29 | 0.11 | 38.44% |
| Q2 2022 Q2Q % growth | -0.29 -141.67% | -0.36 | 0.07 | 18.77% |
| Q1 2022 Q2Q % growth | -0.40 -300.00% | -0.29 | -0.11 | -40.06% |
| Q4 2021 Q2Q % growth | -0.22 -259.48% | -0.26 | 0.04 | 13.73% |
| Q3 2021 Q2Q % growth | -0.12 -96.08% | -0.24 | 0.12 | 49.94% |
| Q2 2021 Q2Q % growth | -0.12 | -0.24 | 0.12 | 50.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 12% | 12% | -0.99% | 22.96% |
| Revenue | N/A | N/A | N/A | N/A |